gastric inhibitory polypeptide

Summary

Summary: A gastrointestinal peptide hormone of about 43-amino acids.

Top Publications

  1. ncbi Biology of incretins: GLP-1 and GIP
    Laurie L Baggio
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 132:2131-57. 2007
  2. ncbi The biology of incretin hormones
    Daniel J Drucker
    Department of Medicine, The Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Ontario M5G 2C4, Canada
    Cell Metab 3:153-65. 2006
  3. doi Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    H E Parker
    Cambridge Institute for Medical Research, Addenbrooke s Hospital, Wellcome Trust MRC Building, Hills Road, Cambridge CB2 0XY, UK
    Diabetologia 52:289-98. 2009
  4. ncbi Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    J Clin Endocrinol Metab 88:2706-13. 2003
  5. pmc Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans
    Meena Asmar
    1Department of Clinical Physiology Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark
    Diabetes 59:2160-3. 2010
  6. pmc The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism
    Francesco Rubino
    IRCAD EITS, Strasbourg, France
    Ann Surg 240:236-42. 2004
  7. ncbi Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
    F C Lynn
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Diabetes 50:1004-11. 2001
  8. doi Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo
    Yukihiro Fujita
    Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    Am J Physiol Endocrinol Metab 296:E473-9. 2009
  9. ncbi Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    Michael J Theodorakis
    Diabetes Section, Laboratory of Clinical Investigation, National Institute of Health, Baltimore, MD 21224, USA
    Am J Physiol Endocrinol Metab 290:E550-9. 2006
  10. ncbi Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Regul Pept 114:115-21. 2003

Detail Information

Publications254 found, 100 shown here

  1. ncbi Biology of incretins: GLP-1 and GIP
    Laurie L Baggio
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Banting and Best Diabetes Centre, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 132:2131-57. 2007
    ..Recently approved therapeutic agents based on potentiation of incretin action provide new physiologically based approaches for the treatment of type 2 diabetes...
  2. ncbi The biology of incretin hormones
    Daniel J Drucker
    Department of Medicine, The Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Ontario M5G 2C4, Canada
    Cell Metab 3:153-65. 2006
    ..This article summarizes current concepts of incretin action and highlights the potential therapeutic utility of GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes...
  3. doi Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells
    H E Parker
    Cambridge Institute for Medical Research, Addenbrooke s Hospital, Wellcome Trust MRC Building, Hills Road, Cambridge CB2 0XY, UK
    Diabetologia 52:289-98. 2009
    ..The aim of this study was to generate transgenic mice with fluorescently labelled GIP-secreting K cells and to use these to investigate pathways by which K cells detect nutrients...
  4. ncbi Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    J Clin Endocrinol Metab 88:2706-13. 2003
    ....
  5. pmc Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans
    Meena Asmar
    1Department of Clinical Physiology Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark
    Diabetes 59:2160-3. 2010
    ..In humans, however, there is no clear evidence of GIP effecting lipid metabolism. The present experiments were performed in order to elucidate the effects of GIP on regional adipose tissue metabolism...
  6. pmc The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism
    Francesco Rubino
    IRCAD EITS, Strasbourg, France
    Ann Surg 240:236-42. 2004
    ..We speculated that if the mechanism of action of the RYGB involves an endocrine effect, then hormonal changes should occur early after surgery, prior to substantial body weight changes...
  7. ncbi Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats
    F C Lynn
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Diabetes 50:1004-11. 2001
    ..These data suggest that the decreased effectiveness of GIP in the VDF rat and in type 2 diabetes may be a result of a decreased receptor expression in the islet...
  8. doi Incretin release from gut is acutely enhanced by sugar but not by sweeteners in vivo
    Yukihiro Fujita
    Department of Cellular and Physiological Sciences, University of British Columbia, Vancouver, BC, Canada V6T 1Z3
    Am J Physiol Endocrinol Metab 296:E473-9. 2009
    ..Collectively, our findings do not support the concept that release of incretins from enteroendocrine cells is triggered by carbohydrates via a pathway identical to the sensation of "sweet taste" in the tongue...
  9. ncbi Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP
    Michael J Theodorakis
    Diabetes Section, Laboratory of Clinical Investigation, National Institute of Health, Baltimore, MD 21224, USA
    Am J Physiol Endocrinol Metab 290:E550-9. 2006
    ..Significant coexpression of the main incretin peptides occurs in human duodenum. L and K cells are present in equal numbers. New onset type 2 diabetes is associated with a shift to the L phenotype...
  10. ncbi Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects
    Tina Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
    Regul Pept 114:115-21. 2003
    ....
  11. ncbi Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo
    Erin B Ramshur
    Department of Internal Medicine, Division of Metabolism, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Cell Physiol 192:339-50. 2002
    ..These results provided unexpected insights into K-cell physiology and our experimental strategy could be easily modified to isolate/characterize additional EE cell populations...
  12. doi Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications
    N Irwin
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co Londonderry, BT52 1SA, UK
    Diabetologia 52:1724-31. 2009
    b>Gastric inhibitory polypeptide (GIP) is a physiological gut peptide secreted from the intestinal K-cells with well documented insulin-releasing actions...
  13. pmc Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet
    Matthew C Althage
    Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, Saint Louis, MO 63110, USA
    J Biol Chem 283:18365-76. 2008
    ..In conclusion, studies using GIP/DT mice demonstrate an important role for K cells in the regulation of body weight and insulin sensitivity...
  14. ncbi Gastric inhibitory polypeptide: the neglected incretin revisited
    Juris J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791, Bochum, Germany
    Regul Pept 107:1-13. 2002
    ..so-called "incretin effect" is primarily conferred by Glucagon-like peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP)...
  15. doi Impaired regulation of the incretin effect in patients with type 2 diabetes
    Jonatan I Bagger
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, DK 2900 Copenhagen, Denmark
    J Clin Endocrinol Metab 96:737-45. 2011
    ..Whether patients with type 2 diabetes mellitus (T2DM) are able to regulate their incretin effect is unknown...
  16. doi Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion
    Yukihiro Fujita
    Laboratory of Molecular and Cellular Medicine, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
    Gastroenterology 138:1966-75. 2010
    ..Interestingly, a subset of enteroendocrine cells express both GIP and GLP-1. We sought to determine whether GIP also might be co-expressed with proglucagon in pancreatic alpha-cells...
  17. pmc Impact of glucose-dependent insulinotropic peptide on age-induced bone loss
    Ke Hong Ding
    Institute of Molecular Medicine and Genetics, Program in Regenerative Medicine, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Bone Miner Res 23:536-43. 2008
    ..We show for the first time that BMSCs express functional GIP receptors, that expression decreases with aging, and that elevations in GIP can prevent age-associated bone loss...
  18. ncbi Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal
    A B Goldfine
    Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA
    J Clin Endocrinol Metab 92:4678-85. 2007
    ..The etiology of the syndrome and metabolic characteristics remain incompletely understood. Recent studies suggest that levels of incretin hormones are increased after GB and may promote excessive beta-cell function and/or growth...
  19. pmc Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors
    Frederic Preitner
    Institute of Pharmacology and Toxicology, Lausanne, Switzerland
    J Clin Invest 113:635-45. 2004
    ....
  20. doi Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver
    Giovanni Musso
    Gradenigo Hospital, Turin, Italy
    Am J Clin Nutr 89:558-67. 2009
    ..We hypothesized that altered GIP secretion may contribute to the pathogenesis of NAFLD...
  21. pmc Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
    Minako Yamaoka-Tojo
    Department of Rehabilitation, Kitasato University School of Allied Health Sciences, 1 15 1 Kitasato, Minami Ku, Sagamihara, 252 0373, Japan
    Cardiovasc Diabetol 9:17. 2010
    ..In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role in MetS are largely unknown...
  22. pmc Effect of the artificial sweetener, sucralose, on gastric emptying and incretin hormone release in healthy subjects
    Jing Ma
    University of Adelaide, Discipline of Medicine, Royal Adelaide Hospital, North Terr, Adelaide SA 5000, Australia
    Am J Physiol Gastrointest Liver Physiol 296:G735-9. 2009
    ..4 mM (73.7+/-3.1 min) or 4 mM (76.7+/-3.1 min) and saline. We conclude that sucralose, delivered by intragastric infusion, does not stimulate insulin, GLP-1, or GIP release or slow gastric emptying in healthy humans...
  23. doi Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion
    Mayumi Okawa
    Tsukuba Research Institute, Banyu Pharmaceutical Company, Ltd, Tsukuba, Ibaraki 300 2611, Japan
    Biochem Biophys Res Commun 390:377-81. 2009
    ..These findings suggest that synthesis and/or secretion of triglyceride-rich lipoproteins play an important role in the release of GIP. Moreover, DGAT1 may directly regulate the release of GLP-1 and PYY in L-cells...
  24. ncbi Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes
    Soushou Lee
    Department of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, 1 5 8 Hatanodai, Shinagawa ku, Tokyo, Japan
    Endocr J 57:119-26. 2010
    ..We concluded that intact GLP-1 levels are comparable between non-diabetics and T2DM, suggesting that impaired insulin secretion in Japanese T2DM is not attributable to defect in GLP-1 secretion...
  25. pmc Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes
    BLANDINE LAFERRERE
    St Lukes Roosevelt Hospital, Obesity Research Center, 1111 Amsterdam Avenue, New York, NY 10025, USA
    J Clin Endocrinol Metab 93:2479-85. 2008
    ..Gastric bypass surgery (GBP) results in rapid weight loss, improvement of type 2 diabetes (T2DM), and increase in incretins levels. Diet-induced weight loss also improves T2DM and may increase incretin levels...
  26. ncbi The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
    Andrea El-Ouaghlidi
    Diabeteszentrum Bad Lauterberg, Kirchberg 21, D 37431 Bad Lauterberg im Harz, Germany
    J Clin Endocrinol Metab 92:4165-71. 2007
    ..the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP)...
  27. doi Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas
    J de Heer
    Department of Biomedical Sciences, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK 2200, Copenhagen N, Denmark
    Diabetologia 51:2263-70. 2008
    ..We examined whether the islet hormone somatostatin, which strongly inhibits glucagon secretion, is involved in this divergent behaviour...
  28. ncbi Evaluation of the long-term effects of gastric inhibitory polypeptide-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice
    Nigel Irwin
    School of Biomedical Sciences Research Institute, SAAD Centre for Pharmacy and Diabetes, University of Ulster, Coleraine, UK
    Br J Nutr 108:46-56. 2012
    The effects of active immunisation with gastric inhibitory polypeptide (GIP) or (proline3)GIP-ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy expenditure and cognition were examined in high-fat-fed mice...
  29. doi Coingestion of acylglycerols differentially affects glucose-induced insulin secretion via glucose-dependent insulinotropic polypeptide in C57BL/6J mice
    Akira Shimotoyodome
    Biological Science Laboratories, Kao Corporation, Tochigi 321 3497, Japan
    Endocrinology 150:2118-26. 2009
    ..DAG promotes a lower GIP and thereby reduced insulin responses compared with triacylglycerol, which may differentially influence postprandial energy homeostasis...
  30. ncbi Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland BT52 1SA, UK
    Diabetes 54:2436-46. 2005
    Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide [GIP]) is an important incretin hormone secreted by endocrine K-cells in response to nutrient ingestion...
  31. pmc Nutrient detection by incretin hormone secreting cells
    Eleftheria Diakogiannaki
    Cambridge Institute for Medical Research and Department of Clinical Biochemistry, Addenbrooke s Hospital, Cambridge, UK
    Physiol Behav 106:387-93. 2012
    ..This review focuses on the molecular mechanisms to detect nutrient arrival in the gut that have been implicated within the incretin secreting cells...
  32. pmc Impact of short-term high-fat feeding on glucose and insulin metabolism in young healthy men
    Charlotte Brøns
    Steno Diabetes Center, Niels Steensens Vej 1, 2820 Gentofte, Denmark
    J Physiol 587:2387-97. 2009
    ....
  33. pmc Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding
    Judith Korner
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    Surg Obes Relat Dis 3:597-601. 2007
    ....
  34. doi The contribution of incretin hormones to the pathogenesis of type 2 diabetes
    Juris J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Best Pract Res Clin Endocrinol Metab 23:433-41. 2009
    ..to defects in the secretion and insulinotropic action of the two main incretin hormones, namely gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1)...
  35. ncbi Differential effects of saturated and monounsaturated fatty acids on postprandial lipemia and incretin responses in healthy subjects
    C Thomsen
    Aarhus Amtssygehus, Aarhus University Hospital, Denmark
    Am J Clin Nutr 69:1135-43. 1999
    ..A direct stimulatory effect of oleic acid on the secretion of glucagon-like peptide 1 (GLP-1) was shown in animal studies...
  36. ncbi Glucose-dependent insulinotropic polypeptide modulates adipocyte lipolysis and reesterification
    Lisa Getty-Kaushik
    Obesity Research Center, Department of Molecular Medicine, Boston University School of Medicine, Boston, MA 02118, USA
    Obesity (Silver Spring) 14:1124-31. 2006
    ....
  37. ncbi Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
    V A Gault
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Northern Ireland, UK
    Diabetologia 50:1752-62. 2007
    b>Gastric inhibitory polypeptide (GIP) receptor antagonism with (Pro(3))GIP improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure/function in ob/ob mice...
  38. pmc Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism
    Burton M Wice
    Department of Internal Medicine, Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 285:19842-53. 2010
    ..Xenin-25, or molecules that increase acetylcholine receptor signaling in beta-cells, may represent a novel approach to overcome GIP resistance and therefore treat humans with T2DM...
  39. ncbi Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes
    Gary A Herman
    Merck Research Laboratories, Experimental Medicine, Rahway, New Jersey 07065, USA
    J Clin Endocrinol Metab 91:4612-9. 2006
    ..The degree of DPP-4 inhibition and the level of active incretin augmentation required for glucose lowering efficacy after an oral glucose tolerance test (OGTT) were evaluated...
  40. ncbi Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects
    Juris J Meier
    Department of Medicine, St Josef Hospiital, Ruhr University Bochum, Bochum, Germany
    Diabetes 53:S220-4. 2004
    A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a characteristic of patients with type 2 diabetes...
  41. ncbi GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, U K
    J Med Chem 49:1047-54. 2006
    ..These data demonstrate that fatty acid derivatized GIP peptides represent a novel class of long-acting stable GIP analogues for therapy of type 2 diabetes...
  42. pmc Glucose-dependent insulinotropic polypeptide enhances adipocyte development and glucose uptake in part through Akt activation
    Diane H Song
    Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts, USA
    Gastroenterology 133:1796-805. 2007
    ..The purpose of these studies was to characterize the effects of GIP and its receptor (GIPR) in adipocyte development and signaling...
  43. ncbi Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
    J J Meier
    Medizinische Klinik I, St Josef Hospital, Klinikum der Ruhr Universitat Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
    Diabetologia 46:798-801. 2003
    In the isolated perfused pancreas, gastric inhibitory polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose concentrations, but in healthy humans no glucagonotropic effect of GIP has yet been reported...
  44. ncbi Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice
    R A Pederson
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Diabetes 47:1046-52. 1998
    ..These observations suggest that upregulation of the GIP component of the enteroinsular axis, at the levels of GIP secretion and action, modifies the phenotype resulting from interruption of the insulinotropic activity of GLP-1 in vivo...
  45. pmc Pharmacological characterization of human incretin receptor missense variants
    Jean Philippe Fortin
    Molecular Pharmacology Research Center, Molecular Cardiology Research Institute, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA
    J Pharmacol Exp Ther 332:274-80. 2010
    ..The extent to which abnormalities in GIP-R function may lead to physiological changes or affect drug sensitivity in selected populations (e.g., obese, diabetic individuals) remains to be further investigated...
  46. doi Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects
    Jerry R Greenfield
    Cambridge Institute for Medical Research and Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
    Am J Clin Nutr 89:106-13. 2009
    ..We previously demonstrated that glutamine is a potent stimulus of GLP-1 secretion in vitro...
  47. doi Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes
    J E Foley
    Novartis Pharmaceutical Corporation, One Health Plaza, East Hanover, NJ 07936, USA
    Horm Metab Res 40:727-30. 2008
  48. ncbi An extract of Gymnema sylvestre leaves and purified gymnemic acid inhibits glucose-stimulated gastric inhibitory peptide secretion in rats
    T Fushiki
    Department of Food Science and Technology, Faculty of Agriculture, Kyoto University, Japan
    J Nutr 122:2367-73. 1992
    ....
  49. pmc Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice
    M Nagashima
    Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine, 1 5 8 Hatanodai, Shinagawa ku, Tokyo 142 8666, Japan
    Diabetologia 54:2649-59. 2011
    ..We investigated the possibility that glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) can prevent the development of atherosclerosis in Apoe (-/-) mice...
  50. ncbi Glucose-dependent insulinotropic polypeptide stimulation of lipolysis in differentiated 3T3-L1 cells: wortmannin-sensitive inhibition by insulin
    C H McIntosh
    Department of Physiology, University of British Columbia, Vancouver, Canada
    Endocrinology 140:398-404. 1999
    ....
  51. ncbi Dorothy Hodgkin Lecture 2008. Gastric inhibitory polypeptide (GIP) revisited: a new therapeutic target for obesity-diabetes?
    P R Flatt
    School of Biomedical Sciences, University of Ulster, Coleraine
    Diabet Med 25:759-64. 2008
    There is increasing realization that gastric inhibitory polypeptide (GIP) has actions outside of the pancreas and gastrointestinal tract...
  52. pmc Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide
    Scott B Widenmaier
    Department of Cellular and Physiological Sciences and the Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada
    J Biol Chem 284:30372-82. 2009
    ..Inhibition of apoptosis by GIP is therefore mediated via a key pathway involving Akt-dependent inhibition of apoptosis signal-regulating kinase 1, which subsequently prevents the pro-apoptotic actions of p38 MAPK and JNK...
  53. ncbi Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice
    Adriano Maida
    Department of Medicine, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada
    Gastroenterology 137:2146-57. 2009
    ....
  54. pmc Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diab
    Dhananjay Gupta
    Division of Endocrinology, Diabetes, and Metabolism and the Department of Medicine, University of Vermont, Burlington, Vermont, USA
    Diabetes 59:1445-50. 2010
    ..Gene Bank blast for a homologous nucleotide sequence revealed the same PPRE within the rat glucose-dependent insulinotropic polypeptide receptor (GIP-R) promoter sequence. We investigated the role of PPARgamma in GIP-R transcription...
  55. ncbi Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells
    K Moens
    Diabetes Research Center, Vrije Universiteit Brussel, Belgium
    Diabetes 45:257-61. 1996
    ..In conclusion, these data show that stimulation of glucagon, GLP-I, and GIP receptors in rat beta-cells causes cAMP production required for insulin release, while adenylate cyclase in alpha-cells is positively regulated by GIP...
  56. doi On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
    Meena Asmar
    Department of Endocrinology, Hvidovre Hospital, Denmark
    Am J Physiol Endocrinol Metab 298:E614-21. 2010
    ..However, both insulin and GIP lower post-Intralipid FFA concentration, GIP probably via stimulation of insulin secretion, increasing FFA reesterification...
  57. ncbi Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus
    Ronald H Clements
    Department of Surgery, Section of Gastrointestinal Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Am Surg 70:1-4; discussion 4-5. 2004
    ..for demographics and fasting levels of the following: glucose, insulin, C-peptide, glucagon, cortisol, gastric inhibitory polypeptide (GIP), and glucagon-like peptide-1 (GLP-1)...
  58. doi Carriers of the TCF7L2 rs7903146 TT genotype have elevated levels of plasma glucose, serum proinsulin and plasma gastric inhibitory polypeptide (GIP) during a meal test
    A P Gjesing
    Steno Diabetes Center, Hagedorn Research Institute, Gentofte, Denmark
    Diabetologia 54:103-10. 2011
    ..insulin, C-peptide, glucagon, glucagon-like peptide-1 (GLP-1), glucagon-like peptide-2 (GLP-2) and gastric inhibitory polypeptide (GIP) among individuals carrying the high-risk rs7903146 TT genotype and low-risk CC genotype ..
  59. doi The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes
    Asger Lund
    Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, Hellerup, Denmark
    Am J Physiol Endocrinol Metab 300:E1038-46. 2011
    ..Our results indicate that the intestinal hormones, GIP, GLP-1, and GLP-2, may play a role in the inappropriate glucagon response to orally ingested glucose in T2DM with, especially, GIP, acting to increase glucagon secretion...
  60. ncbi Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors
    R J Bollag
    Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta 30912, USA
    Endocrinology 141:1228-35. 2000
    ..Both of these effects reflect anabolic actions of presumptive osteoblasts. These results provide the first evidence that GIP receptors are present in bone and osteoblast-like cells and that GIP modulates the function of these cells...
  61. ncbi Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)
    S A Hinke
    Department of Physiology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    Biochim Biophys Acta 1547:143-55. 2001
    ..Higher doses of GIP(1-14) and GIP(19-30) (100 pmol/min/100 g) also reduced blood glucose excursions...
  62. ncbi Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
    M B Toft-Nielsen
    Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, DK-2650 Hvidovre, Denmark
    J Clin Endocrinol Metab 86:3717-23. 2001
    ..We conclude that the meal-related glucagon-like peptide-1 response in type 2 diabetes is decreased, which may contribute to the decreased incretin effect in type 2 diabetes...
  63. ncbi Effects of glucose-dependent insulinotropic peptide on osteoclast function
    Qing Zhong
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Am J Physiol Endocrinol Metab 292:E543-8. 2007
    ..These data are consistent with the hypothesis that GIP inhibits bone breakdown through a direct effect on osteoclast-resorptive activity and suggest one mechanism for the postprandial reduction in markers of bone breakdown...
  64. ncbi Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance
    Kirsten Vollmer
    Department of Medicine I, St Josef Hospital, Ruhr University Bochum, Gudrunstr 56, 44791 Bochum, Germany
    Diabetes 57:678-87. 2008
    ..in GLP-1 levels different after mixed meal or isolated glucose ingestion? 2) Which endogenous factors are associated with the concentrations of GLP-1? In particular, do elevated fasting glucose or glucagon levels diminish GLP-1 responses?..
  65. ncbi Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action
    Heying Zhou
    Department of Diabetes and Clinical Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan
    Biochem Biophys Res Commun 335:937-42. 2005
    Gut hormone gastric inhibitory polypeptide (GIP) stimulates insulin secretion from pancreatic beta-cells upon ingestion of nutrients...
  66. ncbi Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes
    J J Meier
    Department of Medicine I, St Josef Hospital, Ruhr University of Bochum, Bochum, Germany
    Diabetologia 48:1872-81. 2005
    The insulinotropic effect of gastric inhibitory polypeptide (GIP) is reduced in patients with type 2 diabetes and around 50% of their first-degree relatives under hyperglycaemic conditions...
  67. doi Glucose-dependent insulinotropic polypeptide (GIP) stimulates transepithelial glucose transport
    Satish K Singh
    Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA
    Obesity (Silver Spring) 16:2412-6. 2008
    ..GIP stimulates cellular accumulation of cAMP and thereby upregulates glucose transport. The GIP-induced increase in glucose transport appears to be mediated, at least in part, by SGLT-1...
  68. ncbi Changes in insulin resistance following bariatric surgery: role of caloric restriction and weight loss
    Andrew A Gumbs
    Department of Surgery, Yale University School of Medicine, New Haven, CT, USA
    Obes Surg 15:462-73. 2005
    ..Observed changes in glucose metabolism and insulin resistance following bariatric surgery do not require the posit of novel regulatory mechanisms...
  69. ncbi A mathematical model of the oral glucose tolerance test illustrating the effects of the incretins
    Patricia L Brubaker
    Department of Physiology, University of Toronto, Toronto, Canada
    Ann Biomed Eng 35:1286-300. 2007
    ....
  70. ncbi Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, BT52 1SA, United Kingdom
    Biochem Biophys Res Commun 290:1420-6. 2002
    ....
  71. ncbi Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice
    F Isken
    Department of Clinical Nutrition, German Institute of Human Nutrition, Potsdam Rehbruecke, Germany
    Diabetologia 52:2159-68. 2009
    ..Different effects of these diets could be age-dependent, as well as mediated, in part, by carbohydrate-induced stimulation of glucose-dependent insulinotrophic polypeptide (GIP) signalling...
  72. doi Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Biol Chem 390:75-80. 2009
    Recent research suggests that long-term ablation of gastric inhibitory polypeptide (GIP) receptor signalling can reverse or prevent many of the metabolic abnormalities associated with dietary and genetically induced obesity-diabetes...
  73. pmc Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain
    Randi Ugleholdt
    Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Biol Chem 286:44632-45. 2011
    ..The study supports a role of the adipocyte GIPr in nutrient-dependent regulation of body weight and lean mass, but it does not support a direct and independent role for the adipocyte or beta-cell GIPr in promoting adipogenesis...
  74. ncbi Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark
    Diabetes 56:1951-9. 2007
    ..These results suggest that the reduced incretin effect is not a primary event in the development of type 2 diabetes, but rather a consequence of the diabetic state...
  75. ncbi In depth analysis of the N-terminal bioactive domain of gastric inhibitory polypeptide
    Simon A Hinke
    Department of Physiology, Faculty of Medicine, University of British Columbia, 2146 Health Sciences Mall, Vancouver, British Columbia, V6T 1Z3, Canada
    Life Sci 75:1857-70. 2004
    b>Gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide (GIP) is an important gastrointestinal regulator of insulin release and glucose homeostasis following a meal...
  76. pmc Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes
    BLANDINE LAFERRERE
    Obesity Research Center, St Luke s Roosevelt Hospital Center, Columbia University College of Physicians and Surgeons, 1111 Amsterdam Ave, New York, NY 10025, USA
    Diabetes Care 30:1709-16. 2007
    ..We hypothesized that in obese patients with type 2 diabetes the impaired levels and effect of incretins changed as a consequence of RY-GBP...
  77. pmc GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis
    Su Jin Kim
    Department of Cellular and Physiological Sciences and the Diabetes Research Group, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
    PLoS ONE 7:e40156. 2012
    ..Together, these studies suggest that, in the context of over-nutrition, transgenic GIP overexpression has the potential to improve hepatic and adipocyte function as well as glucose homeostasis...
  78. doi Circadian rhythms of GIP and GLP1 in glucose-tolerant and in type 2 diabetic patients after biliopancreatic diversion
    G Mingrone
    Department of Internal Medicine, Universita Cattolica S Cuore, Rome, Italy
    Diabetologia 52:873-81. 2009
    ..We tested the hypothesis that the reversibility of insulin resistance and diabetes observed after biliopancreatic diversion (BPD) is related to changes in circadian rhythms of gastrointestinal hormones...
  79. ncbi In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing's syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism
    Jerome Bertherat
    Institut Fédératif de Recherche Multidisciplinaires sur les Peptides 23, Institut National de la Santé et de la Recherche Médicale U413, Department of Endocrinology, Hospital of Boisguillaume, Centre Hospitalier Universitaire of Rouen, France
    J Clin Endocrinol Metab 90:1302-10. 2005
    ..of the two patients who responded in vivo to food intake (H2 and H4) were stimulated in vitro by gastric inhibitory polypeptide. GnRH and human chorionic gonadotropin, but not FSH, stimulated cortisol secretion in patients H2 and ..
  80. ncbi The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype
    T Vilsbøll
    Department of Internal Medicine F, Gentofte Hospital, DK 2900 Hellerup, Denmark
    J Clin Endocrinol Metab 88:4897-903. 2003
    ..In conclusion, lack of GIP amplification of the late-phase plasma insulin response to glucose seems to be a consequence of diabetes mellitus, characterizing most, if not all, forms of diabetes...
  81. ncbi A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes
    Nigel Irwin
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK
    J Pharmacol Exp Ther 314:1187-94. 2005
    ....
  82. ncbi The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance
    Filip K Knop
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Denmark
    Regul Pept 144:123-30. 2007
    ..The incretin effect is reduced and the insulinotropic effect of the incretin hormone glucose-dependent insulinotropic polypeptide (GIP) is abolished in patients with type 2 diabetes mellitus (T2DM)...
  83. ncbi Regulation of glucose-dependent insulinotropic polypeptide release by protein in the rat
    M M Wolfe
    Section of Gastroenterology, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts 02118, USA
    Am J Physiol Gastrointest Liver Physiol 279:G561-6. 2000
    ..The effects of acid on GIP are consistent with a role for GIP as an enterogastrone in the rat...
  84. pmc Stimulation of incretin secretion by dietary lipid: is it dose dependent?
    Stephanie M Yoder
    University of Cincinnati, Department of Pathology and Laboratory Medicine, ML 0507, Cincinnati, OH 45237, USA
    Am J Physiol Gastrointest Liver Physiol 297:G299-305. 2009
    ..As lipid reaches the distal portion of the gut, GLP-1 is secreted in a dose-dependent manner to reduce intestinal motility and enhance proximal fat absorption...
  85. ncbi QTL detection on porcine chromosome 12 for fatty-acid composition and association analyses of the fatty acid synthase, gastric inhibitory polypeptide and acetyl-coenzyme A carboxylase alpha genes
    G Munoz
    Departamento de Mejora Genética Animal, INIA, 28040 Madrid, Spain
    Anim Genet 38:639-46. 2007
    ..Similarly, gastric inhibitory polypeptide (GIP) and acetyl-coenzyme A carboxylase alpha (ACACA) were tested as candidate genes for the second ..
  86. ncbi Impairment of the insulinotropic effect of gastric inhibitory polypeptide (GIP) in obese and diabetic rats is related to the down-regulation of its pancreatic receptors
    S M Younan
    Department of Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt
    Gen Physiol Biophys 26:181-93. 2007
    ..there is a possibility that an important part of the impaired insulin secretion is due to the gastric inhibitory polypeptide (GIP) hormone...
  87. ncbi The cysteine of the cytoplasmic tail of glucose-dependent insulinotropic peptide receptor mediates its chronic desensitization and down-regulation
    C C Tseng
    Section of Gastroenterology, Boston VA Medical Center and Boston University School of Medicine, MA 02118, USA
    Mol Cell Endocrinol 139:179-86. 1998
    ..The data suggest that chronic desensitization and down-regulation of the GIP-R may be mediated by similar mechanisms, and that the cysteine in the carboxyl terminus plays an essential role in regulating both processes...
  88. doi KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes
    Kasper Aaboe
    Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen, Niels Andersens Vej 65, Hellerup DK 2900, Denmark
    J Clin Endocrinol Metab 94:603-8. 2009
    ..With this study we therefore aimed at clarifying the role of K(ATP) channel malfunction in the impaired function of GIP...
  89. ncbi DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP
    V A Gault
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Cell Biol Int 27:41-6. 2003
    ....
  90. ncbi Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9-39)amide in obese diabetic (ob/ob) mice
    Jeremy C Parker
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Biol Chem 388:221-6. 2007
    ..These studies highlight an important role for GIP in obesity-related forms of diabetes, suggesting the possible involvement of GLP-1 in the beneficial actions of GIP receptor antagonism...
  91. doi Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice
    Ryuichi Moriya
    Banyu Tsukuba Research Institute, Merck Research Laboratory, Tsukuba, Ibaraki, Japan
    Am J Physiol Endocrinol Metab 297:E1358-65. 2009
    ..Our findings indicate that SGLT1 serves as the intestinal glucose sensor for glucose-induced incretin secretion and that a noncalorigenic SGLT1 substrate ameliorates hyperglycemia by stimulating incretin secretion...
  92. ncbi Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice
    Nigel Irwin
    Diabetes Research Group, School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Peptides 27:893-900. 2006
    ..These data indicate that long term activation of the GIP receptor by daily treatment with N-AcGIP(LysPAL37) improved glucose tolerance due to enhancement of pancreatic beta cell glucose responsiveness and insulin secretion...
  93. ncbi Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans
    Ola Lindgren
    Department of Clinical Sciences Lund, Lund University, SE 22184 Lund, Sweden
    J Clin Endocrinol Metab 96:2519-24. 2011
    ..The incretin effect is responsible for the higher insulin response to oral glucose than to iv glucose at matching glucose levels. It is not known whether this effect is restricted to glucose only...
  94. doi Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model
    R E Weaver
    Institute of Membrane and System Biology, Faculty of Biological Sciences, University of Leeds, Leeds, UK
    Int J Obes (Lond) 32:1705-11. 2008
    ....
  95. pmc Adaptive selection of an incretin gene in Eurasian populations
    Chia Lin Chang
    Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital Linkou Medical Center, Chang Gung University, Kweishan, Taoyuan 333, Taiwan
    Genome Res 21:21-32. 2011
    ....
  96. ncbi Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations
    Sonali H Tikhele
    Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz E, Mumbai 400 098, India
    J Pept Sci 16:383-91. 2010
    Glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, or GIP), a 42-amino acid incretin hormone, modulates insulin secretion in a glucose-concentration-dependent manner...
  97. ncbi Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes
    Victor A Gault
    School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine BT52 1SA, Northern Ireland, UK
    Biochem Biophys Res Commun 308:207-13. 2003
    ..The purpose of this article was to provide an overview of the biological effects of several GIP modifications and to highlight the potential of such analogues in the treatment of type 2 diabetes and obesity...
  98. pmc Differential responses of the incretin hormones GIP and GLP-1 to increasing doses of dietary carbohydrate but not dietary protein in lean rats
    Stephanie M Yoder
    Department of Pathology, Univ of Cincinnati, OH, USA
    Am J Physiol Gastrointest Liver Physiol 299:G476-85. 2010
    ..Additionally, we found that the GIP-secreting cells were more sensitive than the GLP-1-secreting cells to changes in intestinal carbohydrate content...
  99. ncbi Glucose-dependent insulinotropic peptide (GIP) gene expression in the rat salivary gland
    C C Tseng
    Harvard Digestive Disease Center, Department of Medicine, Harvard Medical School, Boston, MA, USA
    Mol Cell Endocrinol 115:13-9. 1995
    ....
  100. doi Effects of gastric inhibitory polypeptide (GIP) and related analogues on glucagon release at normo- and hyperglycaemia in Wistar rats and isolated islets
    Roslyn S Cassidy
    School of Biomedical Sciences, University of Ulster, Coleraine BT52 1SA, Northern Ireland, UK
    Biol Chem 389:189-93. 2008
    ..However, the GIP agonists N-AcGIP, GIP(Lys37)PAL and N-AcGIP(Lys37)PAL had no effect on glucagon release demonstrating an improved therapeutic potential for the treatment of type 2 diabetes...
  101. pmc (Pro(3))GIP[mPEG]: novel, long-acting, mPEGylated antagonist of gastric inhibitory polypeptide for obesity-diabetes (diabesity) therapy
    P L McClean
    School of Biomedical Sciences, University of Ulster, Coleraine, Northern Ireland, UK
    Br J Pharmacol 155:690-701. 2008
    Antagonism of the gastric inhibitory polypeptide (GIP) receptor with daily injection of proline-3 gastric inhibitory polypeptide ((Pro(3))GIP) can reverse or prevent many of the metabolic abnormalities associated with diet-induced obesity-..

Research Grants110 found, 100 shown here

  1. Leptin and Neuroendocrine Gene Regulation in Obesity
    Judith Korner; Fiscal Year: 2005
    ..abstract_text> ..
  2. Role of Gastrin in the Pathogenesis of Colorectal Cancer
    Michael Wolfe; Fiscal Year: 2007
    ..The answers to these provocative hypotheses can only be achieved by gaining a thorough understanding of the molecular mechanisms by which gastrin exerts its trophic properties. [unreadable] [unreadable]..
  3. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2006
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. [unreadable] [unreadable]..
  4. SURGICAL STUDIES ON METABOLISM OF GI HORMONES
    James Thompson; Fiscal Year: 1980
    ..of development, RIAs for bombesin, motilin, growth hormone, vasocactive intestinal peptide (VIP), gastric inhibitory polypeptide (GIP) and somatostatin. We will continue our studies to validate these assay systems...
  5. Liver Glycogen in Control of Plasma Glucose
    Katarina Borer; Fiscal Year: 2009
    ..This study examines the role of liver glycogen depletion in this phenomenon and seeks to define the timing of meals and exercise and dietary carbohydrate content that are necessary to produce it. ..
  6. 8th International Symposium for VIP, PACAP & Related Peptides
    Victor May; Fiscal Year: 2007
    ..The 8th International Symposium aims to continue that information and technology transfer to accelerate new developments. [unreadable] [unreadable] [unreadable]..
  7. HORMONAL CONTROL OF ADIPOSE TISSUE LIPOPROTEIN LIPASE
    Robert Eckel; Fiscal Year: 1980
    The major objective of this research proposal is to define the roles of glucose, insulin and gastric inhibitory polypeptide in the regulation of adipose tissue lipoprotein lipase...
  8. VIP FAMILY PEPTIDE ANALOGS--GH, INSULIN, GLUCAGON
    David Coy; Fiscal Year: 1993
    Vasoactive intestinal polypeptide (VIP), secretin, glucagon, gastric inhibitory polypeptide (GIP) and, most recently, PHI, growth hormone releasing hormone (GRF) and pituitary adenylate cyclase activating peptide (PACAP) are members of an ..
  9. DEFINITION OF THE PHYSIOLOGICAL PROPERTIES OF GIP
    M Wolfe; Fiscal Year: 2001
    ....
  10. DEFINITION OF THE PHYSIOLOGICAL PROPERTIES OF GIP
    M Wolfe; Fiscal Year: 2000
    ....
  11. DEFINITION OF THE PHYSIOLOGICAL PROPERTIES OF GIP
    M Wolfe; Fiscal Year: 1999
    ....
  12. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2004
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. ..
  13. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2006
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. [unreadable] [unreadable]..
  14. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2003
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. ..
  15. Glucose-dependent Insulinotropic Peptide & Bone Turnover
    Carlos Isales; Fiscal Year: 2005
    ..This in turn may signal GIP as a potential hormone target for pharmacologic intervention in bone pathologies such as osteoporosis. ..
  16. GASTRIC INHIBITORY POLYPEPTIDE IN HEALTH AND DIABETES
    F Service; Fiscal Year: 1980
    ....
  17. Mechanisms of Diabetes Control After Weight Loss Surgery
    BLANDINE LAFERRERE; Fiscal Year: 2005
    ..As more obese diabetic patients undergo GBP, understanding the mechanisms that produce improvement in their diabetes is increasingly important. ..
  18. Mechanisms of Diabetes Control After Weight Loss Surgery
    BLANDINE LAFERRERE; Fiscal Year: 2006
    ..As more obese diabetic patients undergo GBP, understanding the mechanisms that produce improvement in their diabetes is increasingly important. ..
  19. Mechanisms of Diabetes Control After Weight Loss Surgery
    BLANDINE B LAFERRERE; Fiscal Year: 2010
    ..We wish to apply our findings to possible medical alternatives for the treatment of obesity and T2DM. ..
  20. Mechanisms of Diabetes Control After Weight Loss Surgery
    BLANDINE LAFERRERE; Fiscal Year: 2009
    ..We wish to apply our findings to possible medical alternatives for the treatment of obesity and T2DM. ..
  21. Mechanisms of Diabetes Control After Weight Loss Surgery
    BLANDINE B LAFERRERE; Fiscal Year: 2010
    ..We wish to apply our findings to possible medical alternatives for the treatment of obesity and T2DM. ..
  22. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2005
    ..abstract_text> ..
  23. AGE, EXERCISE, DIET--EFFECTS ON GLUCOSE FATTY ACID CYCLE
    John Kirwan; Fiscal Year: 2001
    ..7) Improvements in glucose and fat metabolism at rest and during a HEC after exercise training and dietart intervention are related to changes in body composition and a reduction in abdominal fat. ..
  24. AGE, EXERCISE, DIET--EFFECTS ON GLUCOSE FATTY ACID CYCLE
    John Kirwan; Fiscal Year: 2002
    ..7) Improvements in glucose and fat metabolism at rest and during a HEC after exercise training and dietart intervention are related to changes in body composition and a reduction in abdominal fat. ..
  25. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2005
    ..abstract_text> ..
  26. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2006
    ..abstract_text> ..
  27. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2007
    ..abstract_text> ..
  28. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2004
    ..abstract_text> ..
  29. DIETARY SUPPLEMENT AND EXERCISE ON WEIGHT LOSS, ENERGY EXPENDITURE & BODY COMP
    John Kirwan; Fiscal Year: 1999
    ..data on the effects of the interventions on insulin, leptin and tumor necrosis factor alpha in a young, moderately obese population who are at risk for the development of non-insulin dependent diabetes mellitus ..
  30. AGE, EXERCISE AND DIET EFFECTS ON GLUCOSE AND FATTY ACID
    John Kirwan; Fiscal Year: 1999
    ..7) Improvements in glucose and fat metabolism at rest and during a HEC after exercise training and dietart intervention are related to changes in body composition and a reduction in abdominal fat. ..
  31. AGE, EXERCISE, DIET--EFFECTS ON GLUCOSE FATTY ACID CYCLE
    John Kirwan; Fiscal Year: 1999
    ..7) Improvements in glucose and fat metabolism at rest and during a HEC after exercise training and dietary intervention are related to changes in body composition and a reduction in abdominal fat. ..
  32. Age, Exercise, Diet: Effects on Insulin Resistance
    John Kirwan; Fiscal Year: 2008
    ..abstract_text> ..
  33. EFFECTS OF EXERCISE INDUCED MUSCLE TISSUE DAMAGE & INSULIN SIGNALING
    John Kirwan; Fiscal Year: 1999
    ..abstract_text> ..
  34. Effect of Bariatric Surgery on Mechanisms of Type 2 Diabetes: The B2D Trial
    Philip R Schauer; Fiscal Year: 2010
    ..The proposed research will compare Bariatric Surgery with Intensive Medical Therapy using a randomized control trial in moderately obese patients with type 2 diabetes. ..
  35. AGE, EXERCISE, DIET--EFFECTS ON GLUCOSE FATTY ACID CYCLE
    John Kirwan; Fiscal Year: 2000
    ..7) Improvements in glucose and fat metabolism at rest and during a HEC after exercise training and dietary intervention are related to changes in body composition and a reduction in abdominal fat. ..
  36. Role of GPR40 in the regulation of insulin secretion
    Vincent Poitout; Fiscal Year: 2005
    ..As an alternative approach, we will knock down GPR40 expression in isolated adult mouse islets by RNA silencing using adenoviral technology. ..
  37. Neutral lipid dysregulation of the pancreatic beta-cell
    Vincent Poitout; Fiscal Year: 2001
    ..These experiments will provide important insights into the pathophysiology of beta-cell dysfunction of type 2 diabetes, and have clear implications for the treatment of this disease. ..
  38. Mechanisms of Fatty-Acid Inhibition of the Insulin Gene
    Vincent Poitout; Fiscal Year: 2007
    ..It will provide new therapeutic targets aimed at preserving insulin secretion in type 2 diabetes, a devastating disease that affects more than 18 million Americans. ..
  39. The Significance of Leptin Signals to Neonatal Somatotropes and Gonadotropes
    Gwen Childs; Fiscal Year: 2009
    ..This proposal thus addresses important questions about how leptin can affect reproductive competence at the level of the pituitary. ..
  40. DEFINITION OF THE PHYSIOLOGICAL PROPERTIES OF GIP
    M Wolfe; Fiscal Year: 2001
    ....
  41. Defintion of the Physiological Properties of GIP
    Michael Wolfe; Fiscal Year: 2007
    ..abstract_text> ..
  42. Insulin Regulation Beta Cell Function in Vivo/in Vitro
    Allison Goldfine; Fiscal Year: 2005
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  43. The effect of bariatric surgery on carbohydrate metabolism
    Adrian Vella; Fiscal Year: 2010
    ..Understanding the effect of these interventions on glucose metabolism and GLP-1 secretion (amongst other gut hormones) will immeasurably increase our ability to develop new treatment strategies in individuals affected with diabetes. ..
  44. The Role of Insulin Regulation of Beta Cell Function in Vivo & in Vitro
    Allison Goldfine; Fiscal Year: 2006
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  45. Defintion of the Physiological Properties of GIP
    M Wolfe; Fiscal Year: 2006
    ..abstract_text> ..
  46. The Role of Insulin Regulation of Beta Cell Function in Vivo & in Vitro
    Allison Goldfine; Fiscal Year: 2006
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  47. The Effect of TCF7L2 on Glucose Metabolism
    Adrian Vella; Fiscal Year: 2009
    ..Understanding the effect of this gene on glucose metabolism and GLP-1 secretion will immeasurably increase our ability to target prevention strategies to predisposed individuals. ..
  48. Mechanisms of ileal-induced weight loss
    APRIL STRADER; Fiscal Year: 2005
    ..Together these specific aims will help clarify the mechanisms underlying obesity surgery and may contribute to the development of more effective treatments for obesity. ..
  49. Dissecting the Death Pathway in Islet Beta Cells
    Rohit Kulkarni; Fiscal Year: 2004
    ..abstract_text> ..
  50. The Effect of TCF7L2 on Glucose Metabolism
    Adrian Vella; Fiscal Year: 2007
    ..Understanding the effect of this gene on glucose metabolism and GLP-1 secretion will immeasurably increase our ability to target prevention strategies to predisposed individuals. ..
  51. Bariatric Surgery, Gastric Stimulation: Metabolic Effects
    Judith Korner; Fiscal Year: 2008
    ..The ultimate goal is to use information from these studies for the development of obesity treatments that are less invasive than bariatric surgery and more effective than current pharmacotherapy. ..
  52. STRUCTURE-FUNCTION RELATIONSHIPS OF THE CCK-B RECEPTOR
    Alan Kopin; Fiscal Year: 1993
    ....
  53. STRUCTURE/FUNCTION OF THE CCK-B/GASTRIN RECEPTOR
    Alan Kopin; Fiscal Year: 2000
    ....
  54. Bariatric Surgery, Gastric Stimulation: Metabolic Effects
    Judith Korner; Fiscal Year: 2007
    ..The ultimate goal is to use information from these studies for the development of obesity treatments that are less invasive than bariatric surgery and more effective than current pharmacotherapy. ..
  55. GLP-1 IN NORMAL AND ABNORMAL GLUCOSE TOLERANCE
    DAVID D ALESSIO; Fiscal Year: 2001
    ..The results of these studies will expand the understanding of glucose homeostasis, and promote the development of new strategies to treat type 2 diabetes. ..
  56. Role of Insulin Regulation of Beta Cell Function in Vivo and in Vitro
    Allison Goldfine; Fiscal Year: 2007
    ..These studies may provide a unifying explanation linking the combined defects in insulin secretion and action that underlie type 2 diabetes. ..
  57. Genetic Analysis of Feeding Behavior and Fat Deposition
    Alan Kopin; Fiscal Year: 2009
    ..Outliers will be characterized as described above. We anticipate that the proposed studies will identify novel genes relevant to the pathophysiology of human obesity. ..
  58. The Effect of TCF7L2 on Glucose Metabolism
    Adrian Vella; Fiscal Year: 2009
    ..Understanding the effect of this gene on glucose metabolism and GLP-1 secretion will immeasurably increase our ability to target prevention strategies to predisposed individuals. ..
  59. Studies of Sulfonylurea Receptors and KATP Channels
    Joseph Bryan; Fiscal Year: 2007
    ..x interacts with the L0 linker of SURs to control bursting. (3) To define further the sulfonylurea/glibenclamide binding pocket of SUR1, specifically to identify amino acids in proximity to the meglitinide head group. ..
  60. The role of GLP-1 in normal and abnormal glucose tolerance
    DAVID D ALESSIO; Fiscal Year: 2009
    ..The goal of this project is to understand the different mechanisms by which GLP-1 acts to allow new and more refined applications of this system to the treatment of diabetes. ..
  61. STRUCTURE/FUNCTION OF THE CCK-B/GASTRIN RECEPTOR
    Alan Kopin; Fiscal Year: 1999
    ....
  62. STRUCTURE-FUNCTION RELATIONSHIPS OF THE CCK-B RECEPTOR
    Alan Kopin; Fiscal Year: 1992
    ....
  63. GPCR Variants as Genetic Determinants of Obesity
    Alan Kopin; Fiscal Year: 2009
    ..In Aim 3, combinations of anorexigenic, orexigenic and hedonic receptor variants will be assessed as potential synergistic or additive factors underlying the polygenic basis of obesity and/or other Look AHEAD study endpoints. ..
  64. BRAIN ENERGY METABOLISM AND HYPOGLYCEMIA
    Patrick Boyle; Fiscal Year: 2003
    ..Better metabolic control, the key to the prevention of long-term complications of diabetes, will thus become more achievable. ..
  65. Defintion of the Physiological Properties of GIP
    M Wolfe; Fiscal Year: 2005
    ..abstract_text> ..
  66. Role of GLP-1 in Normal and Abnormal Glucose Tolerance
    DAVID D ALESSIO; Fiscal Year: 2006
    ..The results of these studies will add to the understanding of the regulation of glucose metabolism by GLP-1 and the incretin axis, and contribute to the development of new strategies to treat type 2 diabetes. ..
  67. GPCR Variants as Genetic Determinants of Obesity
    Alan Kopin; Fiscal Year: 2006
    ..In Aim 3, combinations of anorexigenic, orexigenic and hedonic receptor variants will be assessed as potential synergistic or additive factors underlying the polygenic basis of obesity and/or other Look AHEAD study endpoints. ..
  68. Defintion of the Physiological Properties of GIP
    M Wolfe; Fiscal Year: 2004
    ..abstract_text> ..
  69. Leptin and Neuroendocrine Gene Regulation in Obesity
    Judith Korner; Fiscal Year: 2005
    ..Leibel and Dr. Wardlaw, are experienced in basic and clinical research. They are easily accessible, enthusiastic about my projects, and will facilitate my transition to status as an independent investigator. ..
  70. Molecular Analysis of Dopamine 2 Like Receptor Function
    Alan Kopin; Fiscal Year: 2006
    ..Once identified, these genes will be functionally assessed to determine their potential role in dopaminergic signaling. ..
  71. Role of GLP-1 in Normal and Abnormal Glucose Tolerance
    DAVID D ALESSIO; Fiscal Year: 2004
    ..The results of these studies will add to the understanding of the regulation of glucose metabolism by GLP-1 and the incretin axis, and contribute to the development of new strategies to treat type 2 diabetes. ..
  72. Genetic Analysis of Feeding Behavior and Fat Deposition
    Alan Kopin; Fiscal Year: 2007
    ..Outliers will be characterized as described above. We anticipate that the proposed studies will identify novel genes relevant to the pathophysiology of human obesity [unreadable] [unreadable]..
  73. STRUCTURE/FUNCTION OF THE CCK-B/GASTRIN RECEPTOR
    Alan Kopin; Fiscal Year: 2001
    ....
  74. Defintion of the Physiological Properties of GIP
    M Wolfe; Fiscal Year: 2004
    ..abstract_text> ..
  75. STRUCTURE/FUNCTION OF THE CCK-B/GASTRIN RECEPTOR
    Alan Kopin; Fiscal Year: 2004
    ....
  76. GPCR Variants as Genetic Determinants of Obesity
    Alan Kopin; Fiscal Year: 2005
    ..In Aim 3, combinations of anorexigenic, orexigenic and hedonic receptor variants will be assessed as potential synergistic or additive factors underlying the polygenic basis of obesity and/or other Look AHEAD study endpoints. ..